Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Heart failure with preserved ejection fraction or HFpEF, represents nearly 50% of all heart
failure cases and is particularly common in the elderly. The disease has no current treatment
options. Symptoms typically occur during exertion or exercise and is likely the result of
increased cardiac and pulmonary congestion as a result of impaired diastolic function.
Istaroxime is a novel activator of SERCA2a, an important regulator of calcium uptake within
the myocyte. We will test the hypothesis that Istaroxime will improve diastolic function
during exercise in HFpEF patients which in turn will reduce cardiac and pulmonary congestion.